Latest news
Gossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update - Yahoo FinanceYahoo Finance · Fri, 31 Jul 2026 07:00:00 GMTUpdate: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment - Yahoo FinanceYahoo Finance · Tue, 28 Jul 2026 07:00:00 GMTGossamer Bio shares jump after FDA update and seralutinib rights return - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMTGossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMT